Filing Flows › Health Care › Journey Medical (DERM)
Journey Medical (DERM) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Journey Medical (DERM) Q2 2026 earnings results →
Q2 2026 Revenue up 23% year over year to $18.5M · 2¢ of every $1 of revenue lost · operating margin 2.5%
Journey Medical made $18.5M in Q2 2026 (+23% Y/Y): Emrosi $8.1M, Qbrexza $5.1M, Accutane $3.4M. Operating margin 2.5%, net loss $312K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $18.5M in Q2 2026, up 23% year over year and up 16% from the previous quarter. Emrosi was the largest line at 44% of revenue. Emrosi added $5.3M year over year (up 189%), 151% of the total change. Other / legacy declined 68%.
Operating profit was $456K, a 2.5% margin (up 21.6 points year over year). Total costs grew 1% against revenue growth of 23%. The fastest-growing cost line was Cost of revenue (+24%). The quarter ended with a net loss of $312K, narrower than the previous quarter's $2.2M loss. Net interest and other expense of $753K was the main reason.
Operating cash flow was −$1.7M. Non-cash charges added back $1.4M of share-based compensation. Working capital and other items used $2.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $18.5M | +23% | 2.5% | −$312K | −$1.7M |
| Q1 2026 | 10-Q | May 13, 2026 | $16.0M | +22% | -9.3% | −$2.2M | $2.9M |
| Q4 2025 | 10-K | Mar 26, 2026 | $16.1M | +18% | -2.8% | −$1.2M | −$6.3M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $17.6M | +20% | -8.7% | −$2.3M | −$2.4M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $15.0M | +1% | -19.2% | −$3.8M | −$942K |
| Q1 2025 | 10-Q | May 15, 2025 | $13.1M | +0.8% | -25.3% | −$4.1M | −$2.8M |
| Q4 2024 | 10-K | Mar 27, 2025 | $13.6M | -11% | 16.4% | $1.5M | $2.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Journey Medical
We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”).
In its own words, from its 10-K, filed Mar 26, 2026.
Journey Medical against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +23% against the peers' median +10%. Operating margin: 2.5% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| DERM Journey Medical | Q2 2026 | $18.5M | +23% | 2.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Journey Medical 10-Q on SEC EDGAR · CIK 1867066 · Pharmaceutical Preparations
13F: who owns DERM and who is buying
More on DERM
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results